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Glucan particles (GPs) are hollow, porous 2–4 μm microspheres derived from the cell walls of Baker’s yeast (Saccharomyces
cerevisiae). The 1,3-β-glucan outer shell provides for receptor-mediated uptake by phagocytic cells expressing β-glucan receptors.
GPs have been used for macrophage-targeted delivery of soluble payloads (DNA, siRNA, protein, and small molecules)
encapsulated inside the hollow GPs via core polyplex and layer-by-layer (LbL) synthetic strategies. In this communication, we
report the incorporation of nanoparticles as cores inside GPs (GP-NP) or electrostatically bound to the surface of chemically
derivatized GPs (NP-GP). GP nanoparticle formulations benefit from the drug encapsulation properties of NPs and the macro-
phage-targeting properties of GPs. GP nanoparticle formulations were synthesized using fluorescent anionic polystyrene nano-
particles allowing visualization and quantitation of NP binding and encapsulation. Mesoporous silica nanoparticles (MSNs)
containing the chemotherapeutic doxorubicin (Dox) were bound to cationic GPs. Dox-MSN-GPs eﬃciently delivered Dox into
GP phagocytic cells resulting in enhanced Dox-mediated growth arrest.
1. Introduction
The development of eﬀective drug delivery systems presents
multiple challenges, such as issues of drug solubility, target-
ing, in vivo stability and clearance, and toxicity. Nanotech-
nology-based drug delivery systems are a promising ap-
proach to fulfill the need for new delivery systems oﬀering
several advantages, such as high drug binding capacity due
to their large surface area, improved solubility and bioa-
vailability of hydrophobic drugs, extended drug half-life,
improved therapeutic index, reduced immunogenicity, and
the possibility for controlled release [1–3]. Nanoparticles
can also be synthesized with control over average size, size
distribution, and particle shape, all key factors related to cel-
lular uptake mechanisms and improved penetration across
biological barriers. Additionally, some nanoparticles oﬀer the
possibility for combined use as therapeutic and diagnos-
tic/imaging tools. A new term, theranostics, has been recently
proposed to describe these types of nanoparticles [4]. The
successful development of nanoparticle-based delivery sys-
tems is exemplified by the use of nanomaterials for anticancer
drug formulations [5, 6].
A primary challenge to realizing the full promise of nano-
particle-based drug delivery is the lack of optimal strategies
to achieve selective and eﬃcient cellular targeting. Themech-
anism of NP uptake is dependent on particle size and shape
[7–9], and several competing uptake mechanisms result in
undesired processes including oﬀ-target accumulation in
other organs tissues and cells, rapid clearance from in vivo
circulation (especially NPs less than 5 nm) [10, 11], opson-
ization and macrophage clearance [7, 12], and complement
activation by proteins that results in hypersensitivity reac-
tions [13]. NPs can be somewhat targeted by attaching li-
gands with specificity to receptors that are overexpressed
in certain cells (i.e., folate and transferrin receptors in can-
cer cells [14–18]), or targeting cell populations with high
selectivity by grafting specific targeting moieties to cell
surface receptors known to be expressed only on target
cells (i.e., antibodies to target prostate-specific membrane
antigen (PSMA) [19] or galactose to target asialoglycoprotein
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Figure 1: Schematic representation of glucan particle/nanoparticle synthesis strategies.
receptors on hepatocyte cells [20]). Some interfering pro-
cesses can be reduced by coating of the nanoparticles with
a hydrophilic polymer (i.e., PEG polymer brush or stealth
nanoparticles). PEG is a nonimmunogenic, nontoxic, and
protein-binding resistant polymer. PEG coating of nanopar-
ticles prevents opsonization by shielding surface charges, re-
ducing macrophage clearance, increasing steric repulsion of
blood components, and increasing hydrophilicity and in vivo
circulation of NPs [12, 21].
Glucan particles (GPs) are porous, hollow microspheres
that are prepared from Saccharomyces cerevisiae (Baker’s
yeast). The glucan microspheres have an average diameter
of 2–4 microns and are composed of 1,3-D-glucan and
trace amounts of chitin. The 1,3-D-glucan polysaccharide
on the GP surface serves as a ligand for receptor-mediated
cell uptake by phagocytic cells bearing β-glucan receptors
(dectin-1 (D1) receptor and complement receptor 3 (CR3))
[22], such as macrophages and dendritic cells in the immune
system. GP uptake has been demonstrated to be dectin-
1 dependent in vitro [23]. The ability to selectively target
phagocytic cells makes the glucan particle an attractive drug
delivery vehicle for this cell population. The hollow and
porous material properties of GPs allow for the encapsu-
lation, transport, delivery, and release of electrostatically
bound payloads. Previously we have reported the use of GPs
for macrophage-targeted delivery of soluble payload macro-
molecules (i.e., proteins [23], DNA [24], and siRNA [25,
26]), and small drug molecules, such as the antibiotic
rifampicin [27]. However, the use of GPs for small drug mol-
ecule delivery is limited since the majority of small drug mol-
ecules are neutral, monovalent in charge, or insoluble in
water, and such payloads are not easily trapped within glu-
can particles using the polyplex core or LbL encapsulation
methods developed for nucleic acids and proteins.
We report here a new targeted-nanoparticle delivery ap-
plication for glucan particles incorporating insoluble pre-
formed nanoparticles (NPs) of less than 30 nm in diameter
as cores inside glucan particles (GP-NP), or nanoparti-
cles electrostatically bound to the surface of derivatized
glucan particles (NP-GP) (Figure 1). The advantages of
GP nanoparticle encapsulation include: (1) glucan receptor
targeted delivery (2) the encapsulation of payload complexes
that cannot be prepared in situ as the synthetic conditions
are not compatible with glucan particles, (3) the loading
of nanoparticles that can enhance the ability to load small
drug molecules (neutral, hydrophobic drugs) into GPs, and
(4) the incorporation of nanoparticles with an intrinsic
property, such as magnetic nanoparticles, thus increasing the
versatility of the particles, as the same formulation could be
used for drug delivery and the magnetic properties employed
for cell purification or imaging applications [28].
The development of GP nanoparticle-loaded formula-
tions used two types of model nanoparticles: (1) fluorescent
polystyrene nanoparticles of narrow size distribution to
allow for the visualization and characterization by fluo-
rescent techniques and (2) mesoporous silica nanoparticles
(MSNs) for the encapsulation of the chemotherapeutic drug,
doxorubicin to assess biological activity. MSNs are highly
porous nanoparticles prepared from tetraethyl orthosilicate
polymerized on a template such as a surfactant micelle
[29, 30]. Since the discovery of MSNs in 1992, much work
has been done to evaluate these materials for absorption, ca-
talysis, chemical devices, and more recently as drug delivery
agents (i.e., delivery of the cancer drugs camptothecin, pacli-
taxel, doxorubicin [31–33]). MSNs were chosen as a mod-
el nanoparticle because of their ease of synthesis, binding
capacity for small drug molecules, and the possibility of
extending the capabilities of GP-targeted drug delivery to
hydrophobic drugs. We chose to study the delivery of dox-
orubicin (Dox) as a first step in the development of GP ma-
crophage-targeted delivery of chemotherapeutics. Macro-
phages are nondividing diﬀerentiated cells and are resistant
to the cytotoxic DNA replication inhibitor, doxorubicin. Ma-
crophages are known to migrate into solid tumors, and we
hypothesize that they will act as Trojan horses carrying lethal
doses of Dox-GPs into tumors for targeted cancer drug deliv-
ery to rapidly dividing tumor cells.
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2. Materials and Methods
2.1. Materials. Carboxylate-modified red fluorescent nano-
particles and Alamar blue were purchased from Invitrogen
(Carlsbad, CA); glucan particles (GP) were prepared from
Baker’s yeast (Fleishmans Baker’s yeast, AB Mauri Food Inc,
Chesterfield MO, USA) according to a previously published
procedure [24]. Polyethylenimines (PEIs, molecular weight
of 1.2, 10, and 100 kDa) were purchased from Polysciences
(Warrington, PA, USA). All other PEIs, chemicals for the
synthesis of MSNs, and solvents were purchased from Sigma
Aldrich (Allentown, PA, USA) and used as received.Materials
for cell tissue culture experiments were purchased from
Gibco Scientific (Grand Island, NY, USA) or Fisher Scientific
(Fairlawn, NJ, USA).
2.2. Preparation of 20 nm Nanoparticle Cores Inside GPs. Flu-
orescent 20 nm nanoparticles were used at a concentration
of 4.5 × 1015 particles/mL. Dry glucan particles were mixed
with 5 μL nanoparticle suspension/mg GP to obtain a uni-
form paste, incubated at room temperature for 1 h, and the
GP-NP-loaded formulation was lyophilized. This hydration-
loading-lyophilization procedure was repeated using water
(5 μL/mg GP) to hydraulically push nanoparticles into GPs
by capillary action. The dry GP-NPs were hydrated and
washed after the second lyophilization to remove free nano-
particles, sterilized in 70% ethanol at −20◦C, aseptically
washed three times with 0.9% saline, resuspended in 0.9%
saline, counted with a hematocytometer, and GP concen-
tration adjusted to a concentration of 1 × 108 particles/mL.
Samples were evaluated by fluorescence microscopy, flow
cytometry, zeta potential, and for GP-mediated uptake into
phagocytic cells.
2.3. Synthesis of Cationic GPs. GPs (5mg) were resuspended
in 10mLs of water by homogenization. Potassium periodate
(0.4mL of a 1mg/mL solution) was added and the mixture
stirred in the dark at room temperature for at least six
hours. Oxidized GP samples were washed three times with
water, and used immediately for reductive amination synthe-
sis. Cationic polymers (PEIs) and water were added to the
oxidized GP samples (1 μmol PEI/mg GP), and the parti-
cles were resuspended and mixed at room temperature over-
night. The aminated samples were reduced with sodium bor-
ohydride (0.1 g) and incubated at room temperature for 48
hours. The reduced samples were washed with water. Tris
buﬀer (5mLs, pH 7.5, 0.05M) was added and the sample
incubated for 30 minutes. The samples were washed with
water, resuspended in 70% ethanol, and stored overnight
at −20◦C for sterilization, then aseptically washed three
times with 0.9% saline, resuspended in 0.9% saline, particles
counted with a hematocytometer, and the particle suspen-
sions diluted to a concentration of 1 × 108 particles/mL and
stored at −20◦C.
Periodate oxidized glucan particles (n = 5 samples) were
evaluated for aldehyde content using a hydroxylamine hydro-
chloride assay [34]. Oxidized GP samples (5mg) were incu-
bated in 1mL of DMSO at 50◦C for 2 h to dissolve the parti-
cles. The samples were centrifuged to remove insoluble
material (chitin). Hydroxylamine hydrochloride solution
(0.5mL, 0.5N) containing 0.05%w/v methyl orange added
to the samples, and the mixture was incubated at room tem-
perature for 4 hours. The samples were titrated with a
standardized 0.01M sodium hydroxide solution until a red-
to-yellow endpoint was achieved.
The level of PEI coupling in the PEI-GP samples was
measured with a ninhydrin assay. PEI-GP samples (1mg)
were resuspended in 100 μL of water and mixed with 100 μL
of 2%w/v ninhydrin in DMSO. The samples were heated at
100◦C for 20min, cooled to room temperature, and 800 μL of
ethanol was added. PEI samples of diﬀerent concentrations
were also treated with ninhydrin to prepare calibration
curves and determine the linear response range of each of the
PEIs used in the chemical modification of GPs. Absorbance
was measured at 570 nm for the calibration curve controls,
PEI-GP samples, and blank GP controls. A total of three sam-
ples of each PEI-GP were analyzed with the ninhydrin assay.
2.4. Binding of Nanoparticles to Surface Derivatized GPs. GP
or PEI-GP samples (10 μL 1 × 108 part/mL) and rhoda-
mine labeled carboxylated nanoparticles of diﬀerent diam-
eter (20, 100 and 200 nm) were mixed at NP/GP ratios of
1/1, 10/1, and 100/1 in a final volume of 100 μL in 0.9%
saline. The samples were incubated in the dark for 1 hour
and the unbound nanoparticles separated from the GPs con-
taining bound nanoparticles by centrifugation (10000 rpm
for 2min). The samples were then washed with 0.9% saline
(100 μL) to remove unbound nanoparticles from the pellet,
washed pellet samples resuspended in 0.9% saline (100 μL)
and fluorescence of the carboxylate polystyrene nanopar-
ticles (excitation = 580 nm, emission = 605 nm) measured
in all fractions to quantify bound and unbound nanoparti-
cles. The average of at least five measurements was collected
for each experimental condition. NP-GP samples were also
evaluated by zeta potential measurements, flow cytometry,
and fluorescence microscopy. The NP-GP samples were
tested for nanoparticle-binding stability to GPs by incuba-
tion in phosphate buﬀer saline (PBS, pH 7) contain-
ing 10% fetal bovine serum (FBS), or sodium acetate buﬀer
(0.1M, pH 5) over 48 hours. Samples were processed by cen-
trifugation to remove free nanoparticles, washed and super-
natant fractions analyzed for released cPS-NPs, and pelleted
fractions evaluated by fluorescence microscopy to assess
binding of cPS-NPs to GPs.
2.5. Mesoporous Silica Nanoparticles (MSNs). MSN samples
containing phosphate and amine functional groups were pre-
pared by the cocondensation method reported by Lu et al.
[32, 33]. A solution containing cetyl trimethylammonium
bromide (CTAB, 0.5 g) in water (24mLs), and NaOH
(2M, 0.2mL) was heated to 80◦C and stirred vigorously
until the solutes were dissolved. A solution containing
the MSN reagents (tetraethylorthosilicate, TEOS (2.5mLs)
and amino-propyltriethoxysilane, APTS (12 μLs)) were then
added and the mixture stirred at 80◦C for 15 minutes. 3-Tri-
hydroxysilylpropyl methylphosphonate (0.63mL) was added
and the solution was incubated for 2 hours at 80◦C with
stirring. The solution was cooled at room temperature and
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then centrifuged (3,000 g for 20 minutes), washed with
50mLs of methanol, and dried at room temperature. The
CTAB was extracted from the MSN by refluxing the particles
(850mg) in an acidic methanol mixture (90mLs of methanol
and 5mLs of 12.1M HCl) for 24 hours. The particles were
then washed three times with 50mLs of methanol and left to
dry overnight. MSN samples were characterized by dynamic
light scattering (DLS) particle size measurements, and zeta
potential.
2.6. Doxorubicin Binding to MSN. MSN suspensions and
doxorubicin (0–2 μmolDox/mg MSN) were incubated in
1mL of DMSO overnight at room temperature. The samples
were then centrifuged and the supernatant removed. The
Dox-MSN pellets were lyophilized and washed three times
with 1mL of water to remove Dox bound on the outside of
MSN. A total of five Dox-MSN samples were prepared for
each Dox loading concentration. Dox-MSN samples were
resuspended in sterile water at a concentration of 1mg/mL
and stored at −20◦C. The amount of Dox bound to MSN
was quantified by incubating 0.2mg samples of Dox-MSN
in methanol (1mL) overnight at room temperature to
completely extract Dox. Doxorubicin was quantified by
fluorescence spectroscopy (excitation = 480 nm, emission =
550 nm).
2.7. Synthesis of Dox-MSN-PEI-GP. 25 k PEI-GPs, unmod-
ified GPs (10 μL, 1 × 108 particles/mL), and Dox-MSN
nanoparticles (10 μL, 5 × 10−5 to 5 × 10−2 mgDox-MSN/
mL) were mixed at a final volume of 100 μL in 0.9% saline.
The concentration range of Dox-MSN allowed studying
binding to PEI-GP at Dox-MSN/PEI-GP ratios from 0.0005
to 5 pg Dox-MSN/GP. The samples were incubated in the
dark for 1 hour at room temperature and the unbound Dox-
MSN separated from the PEI-GP or GPs-containing bound
nanoparticles by centrifugation (10000 rpm for 2min).
Additional control samples containing only Dox-MSN were
processed in the purification procedure. The samples were
then washed with 0.9% saline (100 μL) to remove unbound
nanoparticles from the pellet, washed pellet samples resus-
pended in 0.9% saline (100 μL), and fluorescence of dox-
orubicin measured in all fractions to quantify amount of
bound and unbound Dox-MSN. The average of at least
three measurements was collected for each experimental
condition. Dox-MSN-PEI-GP and Dox-MSN-GP samples
were also evaluated by zeta potential measurements, and
fluorescence microscopy. The samples were evaluated for
stability by incubation in phosphate buﬀer saline (PBS, pH 7)
containing 10% fetal bovine serum (FBS), or sodium acetate
buﬀer (0.1M, pH 5) over 48 hours. At various time points,
samples were processed by centrifugation to remove free
nanoparticles, washed and supernatant fractions analyzed
by fluorescence spectroscopy to quantify released Dox, and
pellet fractions were analyzed by fluorescence microscopy to
confirm stability of Dox-MSN-PEI-GP samples.
2.8. Dynamic Light Scattering (DLS) and Zeta Potential Meas-
urements. Size and zeta potential of nanoparticle samples
and zeta potential of GP/NP samples were determined
with a Malvern Zetasizer Nano-ZS (Malvern Instruments,
Worcestershire, UK). Solvents and buﬀers were filtered
through 0.22 μmfilters before sample preparation. A suspen-
sion of particles (1mg/mL for nanoparticle samples, 2 ×
106 particles/mL for GP samples) was diluted in 1mL of
20mM Hepes buﬀer, vortexed, and transferred to a 1mL
clear zeta potential cuvette (DTS1061, Malvern). Zeta poten-
tial was collected at 25◦C from −150 to +150mV. The re-
sults are the average three samples. For each sample a
total of 30 measurements were collected and analyzed with
the Dispersion Technology software 4.20 (Malvern) pro-
ducing diagrams of zeta potential distribution versus total
counts. DLS measurements were obtained from samples
in the same zeta potential cells at 25◦C. The average of
20measurements/sample was collected in the size range from
1 nm to 10000 nm. The data were analyzed with the Disper-
sion Technology software producing histograms for particle
size versus % intensity.
2.9. Flow Cytometry (FACS). FACS measurements were ob-
tained using a Becton Dickinson FACSCalibur instrument
(BD, Franklin Lakes, NJ, USA). Samples were prepared for
FACS analysis by binding of 2 × 107 nanoparticles to 2 ×
106 GP particles. The bound NP-GP samples were washed
from unbound nanoparticles and resuspended at 2× 106 GP/
mL in PBS. Unmodified GPs were used as negative control
and rhodamine-labeled GPs as the positive control. The
particles were analyzed with an FL4 laser at 605 nm by col-
lecting an average of 15000 measurements. Gating and anal-
ysis was performed using FlowJo 6.4.2 software.
2.10. Dox-MSN/GP Cell Delivery. Dox-MSN samples were
prepared as described in Section 2.6. Dox-MSN samples
were bound to 25 k PEI-GP or unmodified GP particles
as described in Section 2.7. The samples were prepared by
binding 0–5 × 10−4 mg Dox-MSN/1 × 106 PEI-GP or GPs,
equivalent to 0–5 pg Dox-MSN/glucan particle. The amount
of PEI-GP or GP particles was chosen to test for cell uptake
at a 10 : 1 GP : cell ratio to maximize phagocytic cell uptake.
Based on the binding of Dox to Dox-MSN, the Dox-MSN-
PEI-GP samples contained 0–0.15 nmol Dox. Dox-MSN-
free nanoparticles and soluble Dox (free Dox) were also
evaluated in the same concentration range. These samples
were evaluated for cellular uptake and Dox delivery using
the NIH3T3-D1 cell line. This cell line was derived from
the NIH3T3 fibroblast cell line by the integration of the
dectin-1 gene to produce cells expressing the β-1,3-D-glucan
receptor dectin-1 allowing for eﬃcient GP phagocytosis
[35, 36]. Samples were resuspended in complete DMEM
medium (250 μL) and added to 24 well plates containing
1 × 105 cells in 0.5mL complete DMEM medium. After
incubation for 3 hours at 37◦C under 5% CO2, the cells were
fixed with 1% formalin and observed microscopically for
fluorescent Dox-MSN/PEI-GP phagocytosis. To determine
the eﬀects of Dox-MSN/PEI-GP, Dox-MSN, or free Dox on
cell growth and viability, these samples were incubated for 3
hours with cells as described above, and the cell monolayers
were washed in complete DMEM and incubated for an
additional 48 hours. Alamar blue (50 μL) was added, the cells
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incubated at 37◦C for 2 hrs, and fluorescence was measured,
excitation wavelength = 530 nm, emission wavelength =
590 nm. Fluorescent response is dependent on the reduction
of the Alamar blue indicator by metabolically active cells and
is an indicator of cell number and viability. Growth arrest
was calculated from the fluorescence response of the sample
wells relative to the response of control wells containing
cells incubated in the absence of doxorubicin. The results
are the average of four samples prepared for each Dox-MSN
formulation evaluated for NIH3T3-D1 growth arrest.
3. Results and Discussion
Glucan particles have been used for macrophage-targeted
delivery of a wide range of payload macromolecules [23–
27]. Soluble payloads can be eﬃciently encapsulated inside
GPs by both polyplex and layer-by-Layer (LbL) synthetic
approaches. There is a growing interest to extend the use
of the GP delivery technology for small drug molecules
(i.e., chemotherapeutics and antibiotics). However, GPs have
limitations in the encapsulation of small molecules asmost of
these molecules are neutral in charge and cannot be trapped
by the noncovalent techniques used to assemble macro-
molecule polyplexes inside GPs. Also, hydrophobic drugs
present a challenge for loading inside GPs. The combination
of established nanoparticle encapsulation technologies and
glucan particles oﬀers an attractive opportunity to extend
the use of GPs for macrophage-targeted delivery of small
drug molecules. Here we present the results of model sys-
tems using polystyrene nanoparticles and mesoporous silica
nanoparticles to demonstrate the GP-mediated small drug
molecule delivery as GP-nanoparticle-drug formulations.
3.1. Use of Glucan Particles for Encapsulation or Surface Bind-
ing of Polystyrene (PS) Nanoparticles. Rhodamine-labeled
carboxylate polystyrene nanoparticles (cPS-NPs) were used
as a model system because of their uniform narrow size
distribution, high fluorescent signal, and the ability to cross-
link or bind carboxylate nanoparticles to the surface of cati-
on-modified GPs through electrostatic interactions. cPS-NPs
(20 nm in diameter) were used to prepare nanoparticle cores
encapsulated within the hollow cavity of GPs. The freeze-
thaw cycles during the nanoparticle-loading process caused
nanoparticle aggregation trapping the cPS-NPs inside GPs.
Additionally, the inclusion of a cationic polymer, like
polyethylenimine (PEI) or chitosan, electrostatically cross-
linked the aggregated nanoparticles inside GPs and slowed
down their release. Figure 2 shows microscopic images of
GP nanoparticle cores and receptor-targeted uptake by cells
bearing glucan receptors. cPS-NPs were loaded at a con-
centration of 2.25 × 1013 nanoparticles/mg GP, and mea-
surement of unbound cPS-NPs collected from washing the
GP-cPS NP cores demonstrated that nanoparticle encapsu-
lation eﬃciency was greater than 80%. The high cPS-NP
encapsulation capacity in the hollow cavity in GPs results in
the loading of >30,000, 20 nm cPS-NPs per glucan particle.
However, there is a limit to the size of nanoparticles that
can be encapsulated inside GPs because the average pore
size in the shell of GPs is less than 40 nm. To overcome this
Table 1: PEI surface functionalization results and zeta potential
values of GP and PEI-GPs.
GP sample
PEI surface
functionalization results
μmol PEI/mg GP
Zeta potential peak
(±5mV)
GP — 2.4
1.2 k PEI-GP 0.012 ± 0.002 22.1
1.8 k PEI-GP 0.031 ± 0.021 21.7
10 k PEI-GP 0.015 ± 0.001 21.1
25 k PEI-GP 0.0136 ± 0.003 30.2
100 k PEI-GP 0.0192 ± 0.001 33.3
size limitation, an alternative approach was devised to bind
nanoparticles to the outer GP shell.
Cationic GPs were synthesized by functionalization of the
GP surface with branched PEIs varying in molecular weight.
The cationic PEI-GP library was prepared by reductive
amination of oxidized glucan particles with PEI following
similar procedures reported for other polysaccharides [37].
The 1,3-glycosidic bonds are stable to oxidation; thus
oxidation of glucan particles takes place only at the reduc-
ing terminal glucosemonomers (<2%) in the β-glucan struc-
ture of the particles. This limits the grafting of PEIs to
∼0.12 μmol PEI/mg GP. The yield of periodate oxidation
of the terminal glucose in the particles (60 ± 10%) was
determined using a hydroxylamine hydrochloride assay. This
oxidation step limits the reaction of cationic PEIs by reduc-
tive animation to less than 0.07 μmol PEI/mg GP. Binding of
the cationic polymers to the glucan particles was confirmed
by a ninhydrin test. The results of PEI grafting shown in
Table 1 confirmed that the levels of PEI covalently linked
to GPs ranged from 0.01 to 0.03 μmol PEI/mg GP (15–40%
yield based on a maximum PEI grafting of 0.07 μmol PEI/mg
GP). The molecular weight of PEI does not seem to have
an eﬀect on grafting; therefore, it is likely that accessibility
of the oxidized glucose units on the particle surface is the
controlling parameter in the reaction.
Zeta potential results (Table 1) confirmed the synthesis
of cationic GPs. Zeta potential has been previously used
to follow reaction sequences on nano- and microparticles
[38]. Unmodified GPs are neutral and a significant shift to
a positive potential demonstrated PEI linkage to GPs. One
limitation of zeta potential measurements is the eﬀect of
particle aggregation on zeta potential to establish a quanti-
tative relation between the number of surface groups and
the zeta potential values. The zeta potential results of PEI-GP
samples indicate that enough PEI has been grafted on the GP
surface to shift the zeta potential of neutral GPs to ∼20mV
(low molecular weight PEI) or ∼30mV (high molecular
weight PEI).
Fluorescent anionic carboxylate polystyrene nanoparti-
cles (cPS-NPs) of three diameters (20, 100, and 200 nm)
were used to measure the binding capacity of PEI-GPs and
control GPs. Larger nanoparticles (0.5, 1, and 2 um) were
also evaluated, but quantitative analysis was diﬃcult due to
spontaneous aggregation of cPS-NPs with the GPs. cPS-NP-
loaded GP samples prepared with nanoparticles of 200 nm or
6 Journal of Drug Delivery
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Figure 2: (a) Microscopic images of GPs containing 20 nm anionic fluorescent carboxylate polystyrene nanoparticles. (b) Fluorescent
photomicrographs showing uptake of GP-cPS-NPs by control NIH3T3 fibroblast cells (left) and GP phagocytosing proficient NIH3T3-D1
cells (right).
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Figure 4: Stability of cPS-NP-GP. cPS-NP released from PEI-GP
samples following incubation in PBS + 10% FBS (pH 7) or 0.1M
acetate buﬀer +10% FBS (pH 5).
less in diameter can be separated fromGPs by centrifugation.
The amount of cPS-NPs bound to the GPs was measured
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Figure 5: Zeta potential of (a) 200 nm anionic polystyrene NPs alone, (b) glucan particle (GP) control + cPS-NPs, and (c) 25 k PEI-GP +
cPS-NPs.
from the fluorescence of unbound cPS-NPs collected in the
supernatant and the bound nanoparticles in the NP-GP
pellet fractions. The binding eﬃciency is defined as the ratio
of fluorescence emission measurements of cPS-NPs in the
pellet fraction divided by the input cPS-NPs.
Measured cPS-NP fluorescence in pellet
input
=binding eﬃciency
(1)
Figure 3 shows that the PEI-GPs readily bind cPS-NPs.
The binding eﬃciency of PEI-GPs for fluorescent anionic
polystyrene nanoparticles was carried out at a ratio of 100 : 1
cPS-NPs : glucan particle and ranged from 50 to 90%. The
unmodified GP control had minimal cPS-NP binding. The
content of amines/GP increases with PEI molecular weight;
however, there is no correlation between amine content
(surface charge) and binding eﬃciency indicating that at the
cPS-NP/GP ratio used in the data presented in Figure 3 that
the binding is limited by the nanoparticle concentration. At
lower cPS-NP/GP ratio (10 : 1 or 1 : 1), we measured binding
eﬃciencies higher than 95%. It was not possible to measure
binding at cPS-NP/GP ratios higher than 100 : 1 due to inef-
ficient separation of the excess unbound cPS-NPs from the
GP pellets.
cPS-NP-PEI-GP samples were evaluated for nanoparti-
cle-binding stability at pH 5 and pH 7 in buﬀers containing
10% fetal bovine serum (FBS) to simulate cell uptake con-
ditions. Fluorescence measurements of the released nano-
particles into solution and microscopic evaluation of the
samples after 48 h incubation showed that more than 60%
of the anionic nanoparticles remained bound to the mod-
ified PEI-GP particles (Figure 4). The stability of the elec-
trostatic binding of cPS-NP to PEI-GPs provides for eﬃcient
glucan-mediated uptake of the cPS-NP-PEI-GPs into cells
expressing glucan receptors (Figure 6).
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Figure 6: Microscopic images of (a) GP + 200 nm cPS-NPs and (b) 25 k PEI-GP + 200 nm cPS-NPs. FACS results of (c) GP + 200 nm
cPS-NPs and (d) 25 k PEI-GP + 200 nm cPS-NPs. Microscopic images showing NIH 3T3-D1 uptake of (e) GP + 200 nm cPS-NPs and (f)
25 k PEI-GP + 200 nm cPS-NPs.
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Figure 7: Binding eﬃciency of Dox-MSN binding to 25 k PEI-GP
(the results are the average of three samples).
Zeta potential was also used to demonstrate the binding
of the anionic cPS-NPs to cationic PEI-GPs. The zeta
potential data in Figure 5 shows the binding of cPS-NPs to
cationic GPs as the zeta potential of the cationic GPs shift to
an anionic value (−25mV). Further, the eﬀective separation
of unbound cPS-NPs from the cPS-NP-GP sample is clear
as there is only one peak (cPS-NP-GP) and no evidence
of unbound cPS-NPs at ∼−50mV. In contrast, the zeta
potential of the unmodified control GPs did not significantly
shift following incubation with 200 nm cPS-NPs.
Microscopic evaluation (Figures 6(a) and 6(b)) of these
samples confirmed the binding of the fluorescent nanoparti-
cles to the surface of PEI-GPs with the cPS-NP fluorescence
localized around the perimeter of the GP shells. Unmodified
control GPs did not show fluorescent cPS-NPs rosetting the
GPs. Flow cytometry was used to quantitate the binding
of fluorescent cPS-NPs to unmodified GP and PEI-GPs.
The results, shown in Figures 6(c) and 6(d), confirmed the
fluorescent cPS-NP binding to the PEI-modified GPs. Al-
though the number of 200 nm nanoparticles that can be
bound to the surface of modified GPs (∼70 cPS-NP/GP) is
significantly less than the number of 20 nm particles that can
be trapped inside GPs (>30,000 20 nm cPS-NP/GP), these
two NP formulation strategies allow the use of GPs for the
targeted drug delivery of drug-nanoparticle conjugates over
a wide range of NP sizes and surface chemistries. Figures 6(e)
and 6(f) show NIH3T3-D1 uptake of cPS-NP nanoparticles
bound to 25 k PEI-GP. These particle uptake experiments
demonstrate that cPS-NP electrostatically bound to PEI-GPs
are more eﬃciently delivered to phagocytic cells than cPS-
NP nanoparticles incubated with the control GP particles or
free cPS-NPs. Additionally, the cell uptake experiments us-
ing cPS-NP-PEI-GP samples confirmed the stability results
(Figure 3) of the electrostatically bound samples and that the
low level of PEI surfacemodification of GPs, or the binding of
anionic nanoparticles to the PEI-GP surface had no apparent
impact on glucan-mediated phagocytosis or cellular toxicity.
3.2. Use of Glucan Particles for the Delivery of Mesoporous
Silica Nanoparticles Loaded with Doxorubicin. Many types of
nanoparticles have been used for drug delivery and imaging
(i.e., silica nanoparticles, carbon nanotubes, gold nanoparti-
cles, polymeric nanogels, magnetic iron oxide nanoparticles,
quantum dots, and PLGA nanoparticles [1, 2, 39]). The drug
can be physically trapped within nanoparticles, or chemically
bound to the surface of the NPs. Methods have also been
developed to precisely control particle size. We chose to
studymesoporous silica nanoparticles (MSN) as amodel sys-
tem with GPs because of their ease of synthesis and ability
to trap chemotherapeutic drugs (i.e., doxorubicin). A MSN
sample containing tetraethoxyorthosilicate (TEOS), amino-
propyltriethoxysilane (APTS), and 3-trihydroxysilylpropyl
methylphosphonate was synthesized following the procedure
reported by Lu et al. [32, 33]. The MSN was synthesized
by a co-condensation method and the phosphate compound
selected to have a larger alkyl chain than APTS to provide
a particle with the outermost surface groups corresponding
to anionic phosphate. This prevents aggregation of MSNs
from interparticle hydrogen bonding between surface silanol
groups and amine groups. Successful synthesis of this MSN
sample was confirmed by zeta potential (−31.1 ± 5mV)
and DLS particle size measurements (MSN average size of
120 nm, polydispersity index PDI of 0.4). The broad particle
size distribution and large particle size prevented the use of
MSNs for loading inside GPs. However, the sample contained
anionic phosphate groups allowed for electrostatic binding to
the surface of cationic PEI-GPs.
MSNwas loaded with the chemotherapeutic doxorubicin
(Dox), an anthracycline-type antitumor drug that exerts its
antiproliferative activity via DNA intercalation and inhibi-
tion of DNA synthesis leading to cell death [40, 41]. Limi-
tations in the use of Dox as an antitumor agent include
chronic or acute cardiotoxicity. Dox has been studied using
diﬀerent nanoparticle delivery systems to enhance Dox deliv-
ery, minimize dosage, and reduce toxicity leading to the suc-
cessful development of a liposomal Dox formulation (Doxil).
Dox was loaded into MSNs in DMSO at target concen-
trations ranging from 0 to 2 μmolDox/mg MSN. Following
MSN Dox loading, the Dox-MSN samples were washed
to remove unbound Dox. The amount of Dox loaded
into the MSN samples was quantified by measuring Dox
fluorescence extracted in methanol, and the results showed
that the binding of Dox to MSN was 0.06 μmolDox/mg
MSN, representing 3% of the input load. This binding
is ∼5 times higher than Dox binding to a control MSN
sample without phosphate groups. Other groups have
reported similar Dox-binding capacities with phosphonate
functionalized MSNs (6–8%w/w) and have shown higher
binding to these functionalized MSNs compared to MSN
controls [42]. The Dox-MSN samples were stable in PBS (pH
7) enabling the electrostatic binding of anionic Dox-MSN
to the surface of cationic PEI-GPs. This binding reaction
was monitored by a fluorescence-binding assay (Figure 7),
zeta potential (Figure 8), and confirmed by fluorescent mi-
croscopy (Figure 8, inset). The fluorescence-binding assay
showed eﬃcient and selective binding of Dox-MSN to PEI-
GP at low Dox-MSN concentrations. Higher concentrations
showed a reduction in binding eﬃciency likely due to sat-
uration of available PEI for binding of Dox-MSN. The
level of background binding of Dox-MSN nanoparticles to
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Figure 8: Zeta potential monitoring of Dox-MSN binding to (a) GP and (b) 25 k PEI-GP. Inset, fluorescent microscopic images of Dox-MSN
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Figure 9: Eﬃcient GP-mediated Dox delivery into NIH 3T3-D1 (pictures were taken at 40x magnification).
unmodified GPs corresponds to the fraction of nanoparticles
that were not eﬃciently separated from the glucan particles.
This is seen in Figure 7, both Dox-MSN alone and Dox-MSN
with GP showed similar binding as a result of measuring
the fluorescence of Dox-MSN-free nanoparticles in the pellet
fraction. Dox-MSN-PEI-GP samples were incubated in 0.9%
saline, PBS with 10% fetal bovine serum (FBS), and sodium
acetate buﬀer (pH 5) at 37◦C for 24 h and evaluated by
fluorescence microscopy to confirm stability of Dox-MSN
binding to PEI-GP.
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Zeta potential measurements confirmed the selective
binding of Dox-MSN to PEI-GP. Dox-MSN had a negative
zeta potential corresponding to the outer phosphate groups
of MSN. Binding of anionic Dox-MSN to cationic PEI-
GP shifted the zeta potential of the PEI-GP sample from a
positive to a negative value. In comparison, the zeta potential
shift of the GP sample is minimal confirming that Dox-MSN
does not bind to unmodified GPs. Fluorescent microscopy
confirmed that Dox-MSN binds to cationic PEI-GP but not
GPs.
The Dox-MSN-GP and Dox-MSN-PEI-GP samples were
tested for intracellular Dox delivery, and antiproliferative and
cytotoxic activities in the NIH 3T3-D1 cell line. This cell line
has been genetically modified to express the Dectin-1 glucan
receptor and eﬃciently phagocytoses GPs. Figure 9 shows
that Dox-MSN-PEI-GP more eﬀectively delivered Dox into
NIH3T3-D1 cells than Dox-MSN-GP or Dox-MSN after 3-
hour incubation.
Cells were incubated with varying concentrations of
Dox-MSN-PEI-GP, Dox-MSN-GP, free Dox-MSN, or free
Dox to assess antiproliferative and cytotoxic activities over 48
hours of incubation. Unincorporated materials were washed
away after 3 hours of incubation, a suﬃcient period of
time for eﬃcient GP uptake by NIH 3T3-D1 cells, and the
growth and viability of the cells were followed. High concen-
trations of free Dox or Dox-MSN (>2.5 μg Dox-MSN con-
taining ∼0.15 nmolDox) inhibited cell growth (>60%). As
seen in Figure 10 at a concentration of 0.015 nmolDox the
Dox-MSN-PEI-GP samples showed similar eﬀect as free
Dox, but free Dox-MSN or Dox-MSN-GP samples showed
less growth inhibition. Below the minimum inhibitory con-
centration (MIC) of free Dox (0.0015 nmolDox), there is still
a significant growth inhibition (20–30%) by the Dox-MSN-
PEI-GP formulation (Figure 10) showing the increased eﬃ-
cacy of GP-targeted delivery of Dox-MSN-PEI-GP. Other
groups have reported the use of MSN for delivery of other
chemotherapeutics (i.e., camptothecin) and showed a 10-
fold reduction in the drug concentration compared to free
drug to achieve 50% cell death [32, 33]. The use of PEI-GP
for Dox-MSN delivery allows for a reduction in drug dosage
compared to free Dox or Dox-MSN demonstrating the
advantage of GP-targeted delivery. Future work will focus on
optimization of Dox incorporation into nanoparticles and
controlled release of Dox fromMSN and other nanoparticles
(i.e., gold nanoparticles) to improve cytotoxicity of Dox NP-
GP formulations. These formulations will be evaluated in
dividing tumor cells (i.e., NIH 3T3-D1) and nondividing
primary macrophages, and in cocultivation macrophage-
tumor cell assays to test the hypothesis that macrophages can
act as cell-based carriers of GP-NP-Dox formulations into
tumors. Optimal GP-Dox NP-GP formulations will be test-
ed in vivo for targeted macrophage Dox delivery and accu-
mulation in tumors.
4. Conclusions
We have developed two strategies for the targeted deliv-
ery of nanoparticles into phagocytic innate immune cells.
Nanoparticles of less than 30 nm in diameter were encapsu-
lated within the hollow cavity of GPs (∼36,000 NPs/GP for
20 nmNPs). Larger anionic nanoparticles (>100 nm) were
electrostatically bound to the surface of GPs derivatized
with the cationic polymer PEI allowing for delivery of
∼70 NPs/GP. Mesoporous silica nanoparticles (120 nm) con-
taining doxorubicin were electrostatically bound to PEI-GPs
providing for the targeted delivery of the Dox-MSN-PEI-GPs
to cells capable of phagocytosing glucan particles. At Dox lev-
els below an eﬀective free-drug concentration, an equivalent
amount of Dox-MSN-PEI-GPs eﬃciently delivered suﬃcient
Dox to inhibit the growth of the GP-phagocytic cell line NIH
3T3-D1. These results demonstrate that the NP-GP delivery
system oﬀers the potential of GP-mediated macrophage-
targeted delivery of multiple nanoparticles in a single uptake
event providing for high eﬃciency intracellular drug delivery.
The possibility that macrophages can serve as Trojan horses
carrying and releasing the drug into solid tumors may fur-
ther enhance the in vivo Dox-MSN-PEI-GP antitumor eﬀect.
We are currently studying a variety of drug loaded nanopar-
ticulate formulations that may provide advantages of higher
drug binding capacity and the possibility of controlled re-
lease. In addition, the use of certain types of nanoparticles
(i.e., gold nanoparticles, magnetic iron oxide) may add ther-
anostic properties to the NP-GP delivery system.
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